Summary
Semaglutide has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Type 2 Diabetes would be drug repurposing rather than first-in-human development. This does not mean it is approved for Type 2 Diabetes. ClinicalTrials.gov lists 8 registered trials linking Semaglutide to Type 2 Diabetes: 2 are currently recruiting; 4 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT07558863). The largest enrolment is 1024 participants (NCT06221969). Registration activity spans 2016 to 2026. The literature layer holds 14 publications for this pair: 5 Cochrane reviews, 3 meta-analyses, 1 systematic review and 5 clinical trial publications. The dated items are from 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Type 2 Diabetes Mellitus ranks 767 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 1.6-1.7% at 7 years on standard care (population-level cohorts UK and US).
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 80.0 (trials 30.0, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 2 recruiting, 0 active / not yet recruiting, 4 completed, 2 other |
| Linked publications | 14 (5 Cochrane reviews, 5 clinical trial publications, 3 meta-analyses, 1 systematic review) |
| Agent type | Biologic |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT07558863 | Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes 2026 | recruiting | Phase 4 | 60 |
| NCT05597202 | Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes 2023 | status unknown | Phase 4 | 22 |
| NCT06221969 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor 2024 | completed | Phase 3 | 1,024 |
| NCT03021187 | Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin 2017 | completed | Phase 3 | 731 |
| NCT02906930 | Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only 2016 | completed | Phase 3 | 703 |
| NCT07581145 | Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients 2026 | recruiting | Phase 3 | 52 |
| NCT05950516 | Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes 2023 | status unknown | Phase 3 | 478 |
| NCT06492330 | Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM 2024 | completed | Not applicable | 62 |
Published literature
- Clinical trial publication Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trialAroda VR, Davies MJ, Maaske J et al. · Lancet (London, England) · 2026 · PMID 42259343
- Clinical trial publication Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyRosenstock J, Billings LK, Gajria R et al. · Lancet (London, England) · 2026 · PMID 42251856
- Clinical trial publication Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup AnalysesTuttle KR, Bakris GL, Baeres FMM et al. · Journal of the American College of Cardiology · 2026 · PMID 42233552
- Clinical trial publication Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trialHelsted MM, Fonnesbech-Wulff C, Schaltz NL et al. · The lancet. Diabetes & endocrinology · 2026 · PMID 42173109
- Clinical trial publication Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney diseaseLong W, Ningning L, Weijun H · Pakistan journal of pharmaceutical sciences · 2026 · PMID 42170981
- Cochrane review Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysisZhu X, Wang X, Zhang P et al. · Frontiers in endocrinology · 2026 · PMID 41987895
- Cochrane review Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized TrialsHung CM, Hsu CW, Zeng BS et al. · International journal of molecular sciences · 2026 · PMID 41898482
- Cochrane review Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesityRaveendra K, Joseph T, Kang J et al. · ESC heart failure · 2026 · PMID 41883191
- Cochrane review Economic evaluation of sodium-glucose transporter 2 inhibitors compared with glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: a systematic reviewWang L, Wang Y, Zhao Q · European journal of clinical pharmacology · 2026 · PMID 41811375
- Cochrane review Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-AnalysisPham TP, Vo TM, Nguyen TA et al. · Diabetes, obesity & metabolism · 2026 · PMID 41804851
- Meta-analysis Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studiesChrzanowski J, Walicka M, Burzyński J et al. · PLoS medicine · 2026 · PMID 42166479
- Meta-analysis Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysisCheng PL, Chang HC · Diabetes research and clinical practice · 2026 · PMID 42155605
- Meta-analysis Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-AnalysisLu Y, Chen J, Guo Y et al. · Diabetes, obesity & metabolism · 2026 · PMID 41992023
- Systematic review Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic reviewGunasekaran P, Inban P, Agrawal A et al. · Disease-a-month : DM · 2026 · PMID 41991422
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Semaglutide approved for Type 2 Diabetes?
Semaglutide has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Type 2 Diabetes would be drug repurposing rather than first-in-human development. This does not mean it is approved for Type 2 Diabetes. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Semaglutide in clinical trials for Type 2 Diabetes?
ClinicalTrials.gov lists 8 registered trials linking Semaglutide to Type 2 Diabetes: 2 are currently recruiting; 4 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT07558863). The largest enrolment is 1024 participants (NCT06221969). Registration activity spans 2016 to 2026.
What does the evidence show for Semaglutide in Type 2 Diabetes?
Semaglutide has both completed registered trials and synthesis-level publications linked to Type 2 Diabetes. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.